5-氨基-N,2-二羟基苯酰胺 | 170368-41-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 5-氨基-N,2-二羟基苯酰胺
• 中文别名: 5-氨基-N,2-二羟基苯甲酰胺
• 英文名称: 5-aminosalicylohydroxamic acid
• 英文别名: 5-amino-N,2-dihydroxybenzamide；5-amino-salicylhydroxamic acid
• CAS: 170368-41-9
• 化学式: C₇H₈N₂O₃
• mdl: MFCD08361633
• 分子量: 168.152
• InChiKey: ICOMDUSNRQQIOT-UHFFFAOYSA-N

物化性质

• 密度：
  1.508±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  95.6
• 氢给体数：
  4
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-氨基-N,2-二羟基苯酰胺 、 2-咪唑甲醛 以 甲醇 为溶剂， 以82 %的产率得到(E)-5-(((1H-imidazol-2-yl)methylene)amino)-N,2-dihydroxybenzamide
  参考文献：
  名称：

  Cytotoxic Imidazolyl-Mesalazine Ester-Based Ru(II) Complexes Reduce Expression of Stemness Genes and Induce Differentiation of Oral Squamous Cell Carcinoma

  摘要：

  DOI：

  10.1021/acs.jmedchem.3c01092
• 作为产物：
  描述：

  5-氨基水杨酸甲酯 在 盐酸羟胺 、 水 、 sodium hydroxide 作用下， 以 甲醇 为溶剂， 生成 5-氨基-N,2-二羟基苯酰胺
  参考文献：
  名称：

  Cytotoxic Imidazolyl-Mesalazine Ester-Based Ru(II) Complexes Reduce Expression of Stemness Genes and Induce Differentiation of Oral Squamous Cell Carcinoma

  摘要：

  DOI：

  10.1021/acs.jmedchem.3c01092

文献信息

• Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field
  申请人：Naccari Giancarlo

  公开号：US20090118357A1

  公开（公告）日：2009-05-07

  Therefore the present invention relates specifically to the compounds of general formula (I), in which R 1 and R 2 , which may be identical or different, are selected from the group comprising H, —C n H 2n-1 , a linear or branched alkyl group having from 1 to 6 carbon atoms, or together form an aromatic or aliphatic ring with 5 or 6 atoms; R 3 is selected from —CO—CH 3 , —NHOH, —OH, —OR 6 in which R 6 is a linear or branched alkyl group having from 1 to 6 carbon atoms; R 4 is selected from H, a linear or branched alkyl group having from 1 to 6 carbon atoms, phenyl, benzyl, —CF 3 or —CF 2 CF 3 , vinyl or allyl; R 5 , R 7 , R 8 are hydrogen atoms; or R 3 and R 4 , R 4 and R 5 , or R 7 and R 8 together form a ring, fused to the benzene, aromatic or aliphatic ring with 5 or 6 atoms comprising from 1 to 2 heteroatoms selected independently from the group comprising N, O, and use thereof in the medical field.

  因此，本发明特别涉及具有通用公式（I）的化合物，其中R1和R2，可以相同或不同，选自包括H，—CnH2n-1，具有1到6个碳原子的直链或支链烷基，或者共同形成一个含有5或6个原子的芳香族或脂肪族环；R3选自—CO—CH3，—NHOH，—OH，—OR6，其中R6是一个具有1到6个碳原子的直链或支链烷基；R4选自H，具有1到6个碳原子的直链或支链烷基，苯基，苄基，—CF3或—CF2CF3，乙烯基或烯丙基；R5，R7，R8是氢原子；或者R3和R4，R4和R5，或R7和R8共同形成一个环，与苯环，芳香族或脂肪族环融合，含有5或6个原子，并包括1到2个独立选自N，O的杂原子，及其在医疗领域的应用。
• Compounds and their Salts Specific to the PPAR Receptors and the EGF Receptors and their Use in the Medical Field
  申请人：Naccari Giancarlo

  公开号：US20120316230A1

  公开（公告）日：2012-12-13

  The present invention relates to compounds of formula (I), where R 1 and R 2 , which may be identical or different, are selected from the group comprising H, C n H 2n-1 , a linear or branched alkyl group having 1 to 6 carbons, or together form an aromatic or aliphatic ring with 5 or 6 atoms; R 3 is —CO—CH 3 , —NHOH, —OH, or —OR 6 where R 6 is a linear or branched alkyl group having 1 to 6 carbon atoms; R4 is H, linear or branched alkyl group having from 1 to 6 atoms, phenyl, benzyl, —CF 3 or CF 2 CF 3 , vinyl or allyl; R 5 , R 7 , R 8 are hydrogen atoms; or R 3 and R 4 , R 4 and R 5 , or R 7 and R 8 together form a ring, fused to the benzene, aromatic or aliphatic ring with 5 or 6 atoms comprising from 1 to 2 heteroatoms selected independently from the group comprising N, O, and use thereof in the medical field.

  本发明涉及式（I）的化合物，其中R1和R2，可以相同也可以不同，选择自H，CnH2n-1，具有1至6个碳的线性或支链烷基团，或者共同形成一个具有5或6个原子的芳香或脂肪环；R3为—CO—CH3，—NHOH，—OH或—OR6，其中R6为具有1至6个碳的线性或支链烷基团；R4为H，具有1至6个原子的线性或支链烷基团，苯基，苄基，—CF3或CF2CF3，乙烯基或丙烯基；R5，R7，R8为氢原子；或者R3和R4，R4和R5，或R7和R8共同形成一个环，与苯环，芳香或脂肪环共同构成一个具有1至2个杂原子的环，独立选择自N，O的群组；以及在医药领域中的应用。
• Compositions and methods utilizing hydroxamates to scavenge oxidant toxins
  申请人：——

  公开号：US20030171260A1

  公开（公告）日：2003-09-11

  Macromolecule compositions using hydroxamate or oxime groups covalently coupled with biological cells and macromolecules, and in particular, with albumin and acellular hemoglobin, are provided. In particular embodiments, hydroxamate or oxime groups are covalently coupled with acellular hemoglobin and compounded to provide several formulations for a red cell substitute that will possess oxidant toxin-scavenging properties. The invention also provides a method of preventing and treating pathologies related to the actions of oxidant toxins or oxidative stress in a mammal. The method comprises administering to a mammal a therapeutically effective amount of a macromolecule composition comprising a macromolecule coupled with at least one hydroxamate or oxime group.

  提供了使用羟肟酸酯或肟基团与生物细胞和大分子，特别是与白蛋白和无细胞血红蛋白共价偶联的大分子组合物。在特定的实施方案中，羟肟酸酯或肟基团与无细胞血红蛋白共价偶联并复配，以提供多种具有氧化剂毒素清除特性的红细胞替代物配方。本发明还提供了一种预防和治疗与哺乳动物体内氧化剂毒素或氧化应激作用有关的病症的方法。该方法包括向哺乳动物施用治疗有效量的大分子组合物，该组合物包含与至少一个羟酰胺基团或肟基团偶联的大分子。
• PPAR-Gamma Agonists for the Induction of Cationic Antimicrobial Peptide Expression as Immunoprotective Stimulants
  申请人：Baroni Sergio

  公开号：US20110152225A1

  公开（公告）日：2011-06-23

  Rosiglitazone, 5-ASA or structurally analogous Compounds according to the general formula (I): or Compounds according to the general formula (Ia): For the induction of CAMP expression in tissues having PPAR-gamma receptors. Such tissues include epithelia or mucosae tissue having PPAR-gamma receptors and of particular interest is CAMP expression in the gut.
• US8138357B2
  申请人：——

  公开号：US8138357B2

  公开（公告）日：2012-03-20